Elsewhere, celecoxib was reported to inhibit cancer stem cell properties of colorectal cancer (CRC) cells by targeting c-Met activity, raising the possibility that celecoxib anti-tumor effect in TPL2-/- mice was as a result of suppressed c-Met activity 103. The gene discussed is MET; the disease is colorectal carcinoma.